Cosmax BTI Valuation

Is A044820 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A044820 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A044820 (₩8600) is trading above our estimate of fair value (₩4515.32)

Significantly Below Fair Value: A044820 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A044820?

Key metric: As A044820 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A044820. This is calculated by dividing A044820's market cap by their current earnings.
What is A044820's PE Ratio?
PE Ratio	6.8x
Earnings	₩12.01b
Market Cap	₩80.26b

A044820 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	10.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A044820's PE Ratio compare to its peers?

The above table shows the PE ratio for A044820 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	44.2x
A027050 Coreana CosmeticsLtd	119.8x	n/a	₩74.4b
A123690 Hankook Cosmetics	29.3x	n/a	₩98.8b
A052260 HYUNDAI BIOLANDLtd	15.5x	n/a	₩128.0b
A357230 H.PIO	12.2x	n/a	₩113.5b
A044820 Cosmax BTI	6.8x	n/a	₩80.3b

Price-To-Earnings vs Peers: A044820 is good value based on its Price-To-Earnings Ratio (6.8x) compared to the peer average (34.7x).

Price to Earnings Ratio vs Industry

How does A044820's PE Ratio compare vs other companies in the KR Personal Products Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A900120 CXI Healthcare Technology Group	0.7x	n/a	US$15.67m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A044820 is good value based on its Price-To-Earnings Ratio (6.8x) compared to the KR Personal Products industry average (16x).

Price to Earnings Ratio vs Fair Ratio

What is A044820's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A044820 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	6.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A044820's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NeoPharm

₩185.2b

Engages in the manufacturing and sale of skin care products in South Korea.

A092730

₩11,840.00

-9.0%

5.2%

NOVAREXLtd

₩133.5b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,540.00

-0.8%

-32.2%

HuM&C

₩48.6b

Engages in the manufacture and sale of various types of makeup products in South Korea and internationally.

A263920

₩991.00

0.7%

-16.1%